Abstract
There is a considerable paucity of empirical data on the use of clozapine in people with intellectual disability, and to the authors’ knowledge these are the first published data on its use in a patient with trisomy 5p and with a diagnosis of schizophrenia. In this case we describe a patient with learning difficulties and a diagnosis of trisomy 5p and schizophrenia that has responded remarkably to clozapine treatment despite numerous additional clinical risk factors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
